Patents by Inventor Peter W. Glunz

Peter W. Glunz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK
    Patent number: 11673886
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: June 13, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK
    Publication number: 20220356179
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 17, 2021
    Publication date: November 10, 2022
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • 5-membered and bicyclic heterocyclic amides as inhibitors of rock
    Patent number: 11078197
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: August 3, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK
    Publication number: 20210147406
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 20, 2021
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • Spiroheptane salicylamides and related compounds as inhibitors of ROCK
    Patent number: 10829501
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati DeLucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Spiro-fused cyclic ureas as inhibitors of rock
    Patent number: 10787450
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 29, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Mandar Shrikrishna Bodas, Pravin Sudhakar Shirude, Sharanabasappa Patil, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Kumaresan Chinnakotti, Peter W. Glunz
  • Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
    Patent number: 10730858
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 4, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zilun Hu, Cailan Wang, Mimi L. Quan, Peter W. Glunz
  • Spirolactams as inhibitors of ROCK
    Patent number: 10696674
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: June 30, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Indawati DeLucca, Andrew K. Dilger
  • Tricyclic rho kinase inhibitors
    Patent number: 10654860
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: May 19, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wu Yang, Peter W. Glunz, Rajeev S. Bhide, Kamalraj Thiyagarajan
  • SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
    Publication number: 20200131200
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati De Lucca, Donald J.P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashnmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Spiroheptane salicylamides and related compounds as inhibitors of rock
    Patent number: 10611776
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati De Lucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Triazolones and tetrazolones as inhibitors of ROCK
    Patent number: 10562887
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 18, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Natesan Murugesan, Peter W. Glunz, Mandar Shrikrishna Bodas, Navnath Dnyanoba Yadav, Venu Alla
  • SPIROLACTAMS AS INHIBITORS OF ROCK
    Publication number: 20190322664
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 24, 2019
    Inventors: Peter W. Glunz, Indawati DeLucca, Andrew K. Dilger
  • LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS
    Publication number: 20190300510
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or reoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 3, 2019
    Inventors: Zilun Hu, Cailan Wang, Mimi L. Quan, Peter W. Glunz
  • SPIRO-FUSED CYCLIC UREAS AS INHIBITORS OF ROCK
    Publication number: 20190300528
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 3, 2019
    Inventors: Rajeev S. Bhide, Mandar Shrikrishna Bodas, Pravin Sudhakar Shirude, Sharanabasappa Patil, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Kumaresan Chinnakotti, Peter W. Glunz
  • TRICYCLIC RHO KINASE INHIBITORS
    Publication number: 20190276466
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: November 29, 2017
    Publication date: September 12, 2019
    Inventors: Wu Yang, Peter W. Glunz, Rajeev S. Bhide, Kamalraj Thiyagarajan
  • Phthalazinones and isoquinolinones as rock inhibitors
    Patent number: 10385026
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: August 20, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Yan Zou, Mimi L. Quan, Vladimir Ladziata
  • TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK
    Publication number: 20190152956
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: May 26, 2017
    Publication date: May 23, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Natesan Murugesan, Peter W. Glunz, Mandar Shrikrishna Bodas, Navnath Dnyanoba Yadav, Venu Alla
  • SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
    Publication number: 20190016735
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 17, 2019
    Inventors: Leon M. Smith II, Vladimir Ladziata, Indawati De Lucca, Donald J.P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Cyclic ureas as inhibitors of rock
    Patent number: 10123993
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: November 13, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Doree F. Sitkoff, Navnath Dnyanoba Yadav, Mandar Shrikrishna Bodas, Rajeev S. Bhide, Sharanabasappa Patil, Kumaresan Chinnakotti, Prasanna Savanor Maddu Rao, Jeevan Prakash Shetty